ICTMC Conference 2017, ACC Liverpool, 9th May 2017

Slides:



Advertisements
Similar presentations
Protocol Development.
Advertisements

Y. Kaydanova, MD, PhD Associate Professor of Neurology
NEWLY DIAGNOSED EPILEPSY Treatment response in mesial temporal lobe epilepsy with hippocampal atrophy (N=14; 2.5% population) Non-responders (42%) Remission.
Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.
Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Pharmacologic Treatment of Pediatric Headaches El-Chammas K, Keyes J, Thompson N,
Therapy for Post Stroke Epilepsy 台中榮總神經醫學中心 神經內科 R4 田怡婷 2014/08/23.
Anti Epileptic Drugs (AEDs) Sampath Charya, MD, FAAN, FAASM VAMC, Fayetteville, NC.
Pharmacogenomics: Implications for CNS Drug Development in the 21st Century Challenges for Development & Approval – Patient & Funding Agency Perspective.
How are women different from men?
The Effect of AED’s upon Cognition: What we Know Cynthia Smith, PhD Program Director, Division of Neuropsychology The Brain & Spine Institute.
By Ken Hui Yee for PBL Group 7 Case 26 - Seizures.
Epilepsy update Martin Sadler. Issues Who to treat and when to start? Who needs investigations? What to start with? Treatment aims New drugs What to do.
Epilepsy Key slides Saint Valentine- Patron Saint of Epilepsy, martyred for the sake of love.
Good Participatory Practice UNAIDS & AVAC Document Pauline Irungu Global Campaign for Microbicides.
CURRENT STATUS AND FUTURE PERSPECTIVES OF DRUG INFORMATION SYSTEMS T. Tervonen (1), V. Oskuee (1), E.O. de Brock (1), P.A. de Graeff (2), H.L. Hillege.
Systematic Reviews.
1 “Update on Treatment of Seizures & Epilepsy” Bassel F. Shneker, MD Comprehensive Epilepsy Program The Ohio State University October 24, 2009.
Management Antiepileptic Drug Therapy – Goal: completely prevent seizures without causing untoward side effects Treat the underlying conditions – Reverse.
Anticonvulsant Therapy for Traumatic Brain Injury
Improving Access, Improving Lives Video:
Module 3 Finding the Evidence: Pre-appraised Literature.
Management Antiepileptic Drug Therapy – Goal: completely prevent seizures without causing untoward side effects Treat the underlying conditions – Reverse.
Quality of life: a comparison of the perspectives of paid staff, family relatives and individuals with dementia in care homes. Sarah Robertson Division.
RSS Merseyside Meeting, 26 February 2016: Pharmaceutical Statistics Sarah J. Nolan Department of Biostatistics University of Liverpool,
Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy 서울대병원 신경과 R3 김성헌.
“EMA policy on publication of Clinical Data” 27/11/2014SFdS - Journée Annuelle du groupe Biopharmacie & Santé.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
Phone: (513) Toll Free: (877) Website:
Tim Friede Department of Medical Statistics
Issue #66 Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data Clinical Case and Discussion Questions.
Graham Powell MRC HTMR Clinical Research Fellow
Switching to Generic Antiepileptic Drugs (AEDs)
Presentation Developed for the Academy of Managed Care Pharmacy
Risk Communication in Medicines
HEALTH INFORMATION TECHNOLOGY SUMMIT OCTOBER 23, 2004 COMMUNITY-BASED COLLABORATIONS: LEGAL ISSUES: STARK, FRAUD & ABUSE Paul T. Smith, Esq. Partner,
eInfraCentral Portal User requirements and features
Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs) 
Andrew Kampfschulte & Rob Lievense September 16, 2015
The Impact of User Involvement on Information System Projects Bradford R. Eichhorn, DBA and Oya Tukel, PhD submitted to PMJ.
Results of a focus group and questionnaire.
Adult nonconvulsive status epilepticus in a clinical setting: Semiology, aetiology, treatment and outcome  Kjersti Nesheim Power, Arne Gramstad, Nils.
The NICE Citizens Council and the role of social value judgements
Annabelle South MRC Clinical Trials Unit at UCL
Elinor Ben-Menachem, MD, PhD
Meta-analysis of joint longitudinal and event-time outcomes
P r e g n a n c y , E p i l e p s y a n d A n t i e p i l e p t i c d r u g s : N e e d F o r T e r a t o v i g i l a n c e Dwajani S, Errol.
Patient emotions and perceptions of antiepileptic drug changes and titration during treatment for epilepsy  Jesse Fishman, Greg Cohen, Colin Josephson,
Antiepileptic Drugs: Pitting the Old Against the New
SỬ DỤNG THUỐC CHỐNG ĐỘNG KINH AN TOÀN Ở TRẺ EM
The Side Effects of Anti-Epileptic Drugs
Management of Patients with Epilepsy
Seizures and Epilepsy: Introduction
Drug Treatment of Seizures: Antiepileptic Drugs (AEDs)
Mission Impossible. No Way
BIOS:6610 – STATISTICAL METHODS IN CLINICAL TRIALS
Managed Access to NIHR-funded Research Data
Presentation Developed for the Academy of Managed Care Pharmacy
W. Owen Pickrell, Arron S. Lacey, Rhys H. Thomas, Ronan A
Clinical Challenges in Epilepsy
Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model  Ting Wu, Yoko Nagaya, Takahisa.
Tim Wehner, Suganthi Chinnasami, Jan Novy, Gail S. Bell, John S
Anca E. Rapcencu, Dick Lindhout, Saskia Bulk 
What the Editors want to see!
بسم الله الرحمن الرحیم.
Exercise / Physical Activity as Medicine Special interest group
Summary of trial identification and selection
Table e-1 Geometric Mean Ratio 90% Confidence Limit of AUC(0-t)
Presentation Developed for the Academy of Managed Care Pharmacy
Dr Coral Sirdifield Research Fellow
Presentation transcript:

ICTMC Conference 2017, ACC Liverpool, 9th May 2017 Sharing individual participant data from clinical trials: Current practice and future thinking Data User Perspective Sarah Nevitt Department of Biostatistics University of Liverpool Acknowledgements: Professor Catrin Tudur Smith, Professor Tony Marson

Cochrane review: Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data Ten Antiepileptic Drugs Carbamazepine (CBZ) Phenobarbitone (PHB) Oxcarbazepine (OXC) Phenytoin (PHT) Valproate (VPA) Lamotrigine (LTG) Gabapentin (GBP) Topiramate (TPM) Levetiracatam (LEV) Zonisamide (ZNS) 45 pairwise comparisons 77 trials 18045 participants Describe this

Data requesting: then and now Type of trial Requests : 1995 -2005 Requests : 2011 - 2016 Requested Provided Academic 15 trials 6 trials (40%) 27 trials 7 trials (26%) 1803 participants 1008 participants (56%) 2178 participants 801 participants (37%) Government 4 trials 3 trials (75%) 1 trial 0 trials (0%) 1178 participants 1091 participants (93%) 593 participants 0 participants (0%) Pharmaceutical 11 trials 9 trials (81%) 17 trials 8 trials (47%) 2906 participants 2604 participants (90%) 6950 participants 4534 participants (65%) Total 30 trials 18 trials (60%) 45 trials 15 trials (33%) 5887 participants 4703 participants (80%) 9721 participants 5335 participants (55%) Plus IPD from two trials conducted at our own CTRC (2437 participants)

Data requesting: then and now Type of trial Requests : 1995 -2005 Requests : 2011 - 2016 Requested Provided Academic 15 trials 6 trials (40%) 27 trials 7 trials (26%) 1803 participants 1008 participants (56%) 2178 participants 801 participants (37%) Government 4 trials 3 trials (75%) 1 trial 0 trials (0%) 1178 participants 1091 participants (93%) 593 participants 0 participants (0%) Pharmaceutical 11 trials 9 trials (81%) 17 trials 8 trials (47%) 2906 participants 2604 participants (90%) 6950 participants 4534 participants (65%) Total 30 trials 18 trials (60%) 45 trials 15 trials (33%) 5887 participants 4703 participants (80%) 9721 participants 5335 participants (55%) Final total: 12475 out of a total of 18045 eligible participants (69% of total data) from 36 out of the 77 eligible trials (47% of total trials).

Data requesting: then and now Type of trial Requests : 1995 -2005 Requests : 2011 - 2016 Requested Provided Academic 15 trials 6 trials (40%) 27 trials 7 trials (26%) 1803 participants 1008 participants (56%) 2178 participants 801 participants (37%) Government 4 trials 3 trials (75%) 1 trial 0 trials (0%) 1178 participants 1091 participants (93%) 593 participants 0 participants (0%) Pharmaceutical 11 trials 9 trials (81%) 17 trials 8 trials (47%) 2906 participants 2604 participants (90%) 6950 participants 4534 participants (65%) Total 30 trials 18 trials (60%) 45 trials 15 trials (33%) 5887 participants 4703 participants (80%) 9721 participants 5335 participants (55%) Final total: 12475 out of a total of 18045 eligible participants (69% of total data) from 36 out of the 77 eligible trials (47% of total trials).

Data requesting: CSDR 17 requests for pharmaceutical trials 6 requests were made via CSDR – IPD provided for one trial Two trials not complete at the time of request Two trials out of scope to provide data (too old) One trial had country specific restrictions Other requests made directly to the company All of these companies have now joined CSDR (or an equivalent data sharing platform).

Advantages for the data user Clear and structured format for requesting data Fewer unresolved requests Clear route of communication with the data provider ‘Cleaner’ data provided Potentially wider audience for the research

Challenges for the data user Time consuming Legal input required Restricted access to data via portals may not allow some methods of analysis

Data Sharing: Data user perspective References Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database of Systematic Reviews (submitted). Nevitt SJ, Marson AG, Davie B, Reynolds S, Williams L, Tudur Smith C. Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review. BMJ 2017;357:j1390 Thank you for listening! Sarah Nevitt (sjn16@liverpool.ac.uk)